Shares of Complete Genomics Inc. (NASDAQ: GNOM), a life sciences company engaged in the development and commercialization of a deoxyribonucleic acid (DNA) sequencing platform, are continuing to rally.
At last check, GNOM shares were trading 31.76% higher at $3.07 on above average volume of 10 million. The stock rose to an intra-day high of $3.32 today. GNOM has gained more than 88% this week.
Earlier this month, Complete Genomics released its first-quarter financial results. For the quarter ended March 31, 2012, GNOM reported revenue of $3.9 million, compared with $6.8 million reported for the same period in the previous year.
During the quarter, GNOM delivered data for approximately 1,200 genomes, which include over 100 non-revenue generating genomes under the company’s Wellderly and cancer grant programs.
GNOM reported a net loss of $20.2 million for the first quarter, compared with $12.5 million reported for the same period in the previous year.